Relafen 750, chemically known as naproxen, represents a important case study from a pharmaceutical pharmacy standpoint. It's exhibits its medicinal effect primarily by blocking the activity of cyclooxygenase (COX) enzymes, specifically COX-2, thereby decreasing prostaglandin synthesis . The specific inhibition of COX-2, compared to traditional NSAI